4Olson JK, Sood AK, Sorosky JI, et al. Taxol hypersensitivity : rapid retreatment is safe and cost effective [ J]. Gynecol Oncol, 1998,68 ( 1 ) :25-28.
5Markman M, Kennedy A, Webster K, et al. Paclitaxel associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center[ J]. J Clin Oncol, 2000,18 ( 1 ) : 102-105.
4Weiss RB, Donchower RC, Wiemik PH, et al. Hypersensitivity reaction from taxol [J]. J Clin Oncol, 1990;8(7): 1263 - 1268
5Olson JK, Sood AK, Sorosky JI, et al. Taxol hypersensitivity: rapid retreatment is safe and cost effecitive [J]. J Gynecol oncol, 1998; 68 (1):25-28
6Neijt JP, Engelhom SA, Tuxen MK, etal.Exploratory phase study of paclitaxel and cisplatin versus paclitaxel and carboplatinin advanced ovarian cancer.[J].J Clin Oncol,2000,18(17):3084-3092.
7Gatzameier U, Pawel JV, Gottfried M, et al. Phase comparative study of high-dosecisplatin in patients with advanced non-small-cell lung cancer[J].J ClinOncol,2000,18(19):3390-3399.
8Gelmon K, Eisenhauer E, Bryce C, et al. Randomized phaseⅡstudy of high-dosepaclitaxel with or without amifostine in patients with metastatic breast cancer[J].J ClinOncol,1999,17(10):3038-3047.
9Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reaction from taxol[J].J Clin Oncol,1990,8(7):1263-1268.
10Olson JK, Sood AK, Sorosky JI, et al. Taxol hypersensitivity: rapid retreatment issafe and cost effective[J]. J Gynecol Oncol,1998,68(1):25-28.
